{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T15:46:21Z","timestamp":1777477581581,"version":"3.51.4"},"reference-count":10,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2006,10,1]],"date-time":"2006-10-01T00:00:00Z","timestamp":1159660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Appl Thromb Hemost"],"published-print":{"date-parts":[[2006,10]]},"abstract":"<jats:p>\n                    Idiopathic thrombocytopenic purpura (ITP) is an immune-mediated disorder characterized by accelerated and premature destruction of platelets by reticuloendothelial system. CD20, a trans-membrane B-cell-specific antigen, is a potential target for treatment of certain malignant and nonmalignant plasma cell disorders including refractory ITP. Rituximab is a genetically engineered human anti-CD20 monoclonal antibody, which is approved for the treatment of low-grade non-Hodgkin\u2019s lymphoma. Recent clinical reports suggest that rituximab may be useful in treating certain patients with chronic refractory ITP. A 59-year-old woman with refractory ITP was placed on rituximab (four weekly doses of 375 mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    ) and her condition and platelet count were observed for 18 months. There was a gradual increase in platelet count and she was symptom free in this period and no side effects of the drug were reported. Anti-CD20 antibodies are likely to be used in the treatment of refractory ITP cases, but further studies about treatment schedule and criteria for patient selection should be done.\n                  <\/jats:p>","DOI":"10.1177\/1076029606293439","type":"journal-article","created":{"date-parts":[[2007,6,21]],"date-time":"2007-06-21T21:15:00Z","timestamp":1182460500000},"page":"489-492","source":"Crossref","is-referenced-by-count":2,"title":["Chronic Refractory Idiopathic Thrombocytopenic Purpura (ITP) and Anti-CD20 Monoclonal Antibody: A Case Report"],"prefix":"10.1177","volume":"12","author":[{"given":"S. Z.","family":"Latifzadeh","sequence":"first","affiliation":[{"name":"Department of Hemato-Oncology, Rasule-Akram General Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Entezari","sequence":"additional","affiliation":[{"name":"Department of Hemato-Oncology, Rasule-Akram General Hospital, Iran University of Medical Sciences (IUMS), Tehran, Iran,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,10,1]]},"reference":[{"key":"atypb1","first-page":"207","volume":"331","author":"George JN","year":"1995","journal-title":"N Engl J Med"},{"issue":"6","key":"atypb2","first-page":"91","volume":"27","author":"Bussel JB.","year":"2000","journal-title":"Semin Oncol"},{"issue":"6","key":"atypb3","first-page":"99","volume":"27","author":"Saleh MN","year":"2000","journal-title":"Semin Oncol"},{"issue":"6","key":"atypb4","first-page":"79","volume":"27","author":"Treon SP","year":"2000","journal-title":"Semin Oncol"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01273-1"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.4.952"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1016\/S0037-1963(00)90107-0"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1081"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1112"},{"issue":"1","key":"atypb10","first-page":"49a","volume":"94","author":"Perotta A","year":"1999","journal-title":"Blood"}],"container-title":["Clinical and Applied Thrombosis\/Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029606293439","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1076029606293439","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:59:03Z","timestamp":1777384743000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1076029606293439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10]]}},"alternative-id":["10.1177\/1076029606293439"],"URL":"https:\/\/doi.org\/10.1177\/1076029606293439","relation":{},"ISSN":["1076-0296","1938-2723"],"issn-type":[{"value":"1076-0296","type":"print"},{"value":"1938-2723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10]]}}}